Compare MTEK & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MTEK | NEUP |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 10.3M |
| IPO Year | 2022 | N/A |
| Metric | MTEK | NEUP |
|---|---|---|
| Price | $1.34 | $3.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 49.8K | ★ 76.2K |
| Earning Date | 09-26-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,375,716.00 | ★ $15,649,448.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.03 | $3.00 |
| 52 Week High | $5.90 | $21.40 |
| Indicator | MTEK | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 51.26 | 40.99 |
| Support Level | $1.07 | $3.65 |
| Resistance Level | $1.41 | $4.00 |
| Average True Range (ATR) | 0.12 | 0.18 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 61.73 | 44.55 |
Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.